SELLAS Life Sciences Group Inc (SLS)
1.41
+0.01
(+0.71%)
USD |
NASDAQ |
May 31, 16:00
1.415
0.00 (0.00%)
After-Hours: 20:00
SELLAS Life Sciences Group Research and Development Expense (TTM): 21.94M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.94M |
| December 31, 2023 | 24.01M |
| September 30, 2023 | 14.76M |
| June 30, 2023 | 13.22M |
| March 31, 2023 | 12.83M |
| December 31, 2022 | 20.27M |
| September 30, 2022 | 27.82M |
| June 30, 2022 | 28.07M |
| March 31, 2022 | 26.00M |
| December 31, 2021 | 15.67M |
| September 30, 2021 | 15.05M |
| June 30, 2021 | 12.88M |
| March 31, 2021 | 11.70M |
| December 31, 2020 | 9.282M |
| September 30, 2020 | 8.757M |
| June 30, 2020 | 8.189M |
| March 31, 2020 | 7.29M |
| December 31, 2019 | 7.285M |
| September 30, 2019 | 8.69M |
| June 30, 2019 | 8.611M |
| March 31, 2019 | 8.822M |
| December 31, 2018 | 8.767M |
| September 30, 2018 | 5.826M |
| June 30, 2018 | 5.057M |
| March 31, 2018 | 5.292M |
| Date | Value |
|---|---|
| December 31, 2017 | 5.672M |
| September 30, 2017 | 1.115M |
| June 30, 2017 | 3.788M |
| March 31, 2017 | 8.136M |
| December 31, 2016 | 11.40M |
| September 30, 2016 | 20.09M |
| June 30, 2016 | 22.21M |
| March 31, 2016 | 23.23M |
| December 31, 2015 | 23.61M |
| September 30, 2015 | 24.97M |
| June 30, 2015 | 26.26M |
| March 31, 2015 | 27.13M |
| December 31, 2014 | 28.08M |
| September 30, 2014 | 28.30M |
| June 30, 2014 | 24.91M |
| March 31, 2014 | 22.11M |
| December 31, 2013 | 20.42M |
| September 30, 2013 | 18.05M |
| June 30, 2013 | 18.59M |
| March 31, 2013 | 17.03M |
| December 31, 2012 | 14.61M |
| September 30, 2012 | 12.65M |
| June 30, 2012 | 9.845M |
| March 31, 2012 | 6.454M |
| December 31, 2011 | 5.946M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
7.285M
Minimum
Dec 2019
28.07M
Maximum
Jun 2022
15.12M
Average
13.05M
Median
Research and Development Expense (TTM) Benchmarks
| Geron Corp | 127.20M |
| Immuneering Corp | 42.62M |
| Protagonist Therapeutics Inc | 126.48M |
| Akebia Therapeutics Inc | 53.12M |
| Moderna Inc | 4.777B |